Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of EPI-743 in Children With Pearson Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Genetically confirmed diagnosis of Pearson syndrome~* Age less than 18~* Availability of medical history for 12 months prior to enrollment~* Abstention from use of CoQ10, vitamin E, lipoic acid and Idebenone 14 days prior to treatment with EPI-743~Exclusion Criteria:~* Allergy to EPI-743, sesame oil or vitamin E~* Clinical history of bleeding/ abnormal PT/PTT~* Concurrent inborn errors of metabolism~* Use of anticoagulant medications~* Participation in any interventional study within 30 days of treatment~* Use of erythropoietin 30 days prior to trial enrollment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- EPI-743 (Type: EXPERIMENTAL): 15 mg/kg EPI-743 to be administered three times per day for 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).